Sukovatykh B S, Belikov L N, Savchuk O F, Sukovatykh M B
Vestn Khir Im I I Grek. 2014;173(4):87-91.
An analysis of complex examination of 110 patients with venous thromboembolism was made. The patients were separated into 2 groups. The first group included 60 patients, who had the start heparin therapy during 7 days with the following 6-month warfarin therapy. Warfarin was substituted by pradaxa (dabigatran) for 50 patients of the second group. The efficacy of pradaxa could be compared with warfarin. However, pradaxa had a number of advantages such as the predictable anticoagulant effect, standard dosages. This medicine is more predictable and doesn't require a control of homeostasis and an adjustment of drug dosage.
对110例静脉血栓栓塞患者的综合检查进行了分析。患者被分为两组。第一组包括60例患者，他们在7天内开始肝素治疗，随后进行6个月的华法林治疗。第二组的50例患者用达比加群酯（Pradaxa）替代华法林。达比加群酯的疗效可与华法林相比较。然而，达比加群酯有许多优点，如抗凝效果可预测、剂量标准。这种药物更具可预测性，不需要监测体内稳态和调整药物剂量。
